Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients

Table 1 Differences between VAD-chemosensitive (CS) and less VAD-chemosensitive (LCS) patients

	CS [%]	LCS [%]	P-value
Gender			0.99
Male	7 [63.6]	10 [71.4]
female	4 [36.4]	4 [28.6]
Age (median)	49	55	0.217
paraprotein subtype			0.07
G	3 [27.3]	9 [64.3]
A	1 [9.1]	3 [21.4]
D	2 [18.2]	0 [0]
LC	5 [45.5]	2 [14.3]
ISS stage			0.69
I & II	7 [63.6]	7 [50]
III	4 [36.4]	7 [50]
≥VGPR after induction			0.227
No	3 [27.3]	8 [57.1]
Yes	8 [72.7]	6 [42.9]
≥VGPR after ABMT			0.03
No	1 [9.1]	7 [50.0]
Yes	10 [90.9]	7 [50.0]
Oligoclonal reconstitution			0.434
Yes	5 [45.5]	4 [28.6]
no	6 [54.5]	10 [71.4]
DAPK methylation			0.216
methylated	3 [27.3]	1 [7.1]
unmethylated	6 [54.5]	12 [85.7]
unknown	2 [18.2]	1 [7.1]1

G: IgG; A: IgA; D: IgD; LC: light chain myeloma; DS: Durie-Salmon stage; ISS: International staging system; VGPR: >90% reduction in paraprotein level

ISSN: 1479-5876